EA201591568A1 - Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения - Google Patents

Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения

Info

Publication number
EA201591568A1
EA201591568A1 EA201591568A EA201591568A EA201591568A1 EA 201591568 A1 EA201591568 A1 EA 201591568A1 EA 201591568 A EA201591568 A EA 201591568A EA 201591568 A EA201591568 A EA 201591568A EA 201591568 A1 EA201591568 A1 EA 201591568A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oral
application
methods
pharmaceutical composition
sulfate salts
Prior art date
Application number
EA201591568A
Other languages
English (en)
Other versions
EA034234B1 (ru
Inventor
Эдмунд В. Джр. Деннетт
Дэвид С. Уэллс
Original Assignee
Брейнтри Лабораторис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Брейнтри Лабораторис, Инк. filed Critical Брейнтри Лабораторис, Инк.
Publication of EA201591568A1 publication Critical patent/EA201591568A1/ru
Publication of EA034234B1 publication Critical patent/EA034234B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение в целом относится к пероральной фармацевтической таблетированной композиции, содержащей сульфатную соль, например сульфат натрия, при этом композиция является подходящей для введения путем прямого перорального приема и путем дезинтеграции в воде перед пероральным приемом. Изобретение, кроме того, относится к применению таких составов пероральной фармацевтической таблетки для индуцирования перистальтики кишечника или для лечения или предупреждения запора.
EA201591568A 2013-03-15 2014-03-14 Пероральные фармацевтические таблетированные композиции двойного применения, содержащие сульфат натрия или его комбинацию с другими сульфатными солями, и способы их получения и применения EA034234B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798759P 2013-03-15 2013-03-15
PCT/US2014/028805 WO2014144407A1 (en) 2013-03-15 2014-03-14 Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201591568A1 true EA201591568A1 (ru) 2015-12-30
EA034234B1 EA034234B1 (ru) 2020-01-20

Family

ID=50680164

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992382A EA201992382A3 (ru) 2013-03-15 2014-03-14 Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
EA201591568A EA034234B1 (ru) 2013-03-15 2014-03-14 Пероральные фармацевтические таблетированные композиции двойного применения, содержащие сульфат натрия или его комбинацию с другими сульфатными солями, и способы их получения и применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201992382A EA201992382A3 (ru) 2013-03-15 2014-03-14 Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения

Country Status (24)

Country Link
US (2) US9919007B2 (ru)
EP (2) EP2968174B1 (ru)
JP (2) JP6441890B2 (ru)
CN (2) CN105142617B (ru)
AU (3) AU2014227598B2 (ru)
BR (1) BR112015019776A2 (ru)
CA (1) CA2903283C (ru)
CY (1) CY1122387T1 (ru)
DK (1) DK2968174T3 (ru)
EA (2) EA201992382A3 (ru)
ES (1) ES2764462T3 (ru)
HK (1) HK1214519A1 (ru)
HR (1) HRP20192227T1 (ru)
HU (1) HUE046754T2 (ru)
IL (1) IL241367A0 (ru)
LT (1) LT2968174T (ru)
ME (1) ME03656B (ru)
MX (1) MX2015012109A (ru)
PE (1) PE20151543A1 (ru)
PL (1) PL2968174T3 (ru)
PT (1) PT2968174T (ru)
RS (1) RS59667B1 (ru)
SI (1) SI2968174T1 (ru)
WO (1) WO2014144407A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014227598B2 (en) 2013-03-15 2018-12-06 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
WO2016040733A1 (en) * 2014-09-12 2016-03-17 Braintree Laboratories, Inc. Sulfate salt solution laxative compositions and methods of use thereof
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
EP4232008A4 (en) * 2020-10-26 2024-07-10 Braintree Laboratories Inc SALINE SULFATE FORMULATIONS FOR COLON CLEANSING
CN116509809A (zh) * 2023-04-19 2023-08-01 山东齐都药业有限公司 复方硫酸钠片剂及其制备方法与应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873694A (en) 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
JPS5438167B2 (ru) 1974-04-27 1979-11-19
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2058565B (en) 1979-09-21 1983-12-07 Leo Pharm Prod Ltd Layer tablets
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3134591A1 (de) 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPS5839618A (ja) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
EP0080862B1 (en) 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59101423A (ja) 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
JPS6097919A (ja) 1983-11-01 1985-05-31 Furointo Sangyo Kk 圧縮成形用賦形剤の製造方法
NL8400911A (nl) 1984-03-22 1985-10-16 Dagra Nv Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
EP0231356A1 (en) 1985-08-01 1987-08-12 Braintree Laboratories, Inc. Low-sodium laxative and lavage formulation
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
DE3887179T2 (de) 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
NO168563C (no) 1987-09-28 1992-03-11 Collett Marwell Hauge As Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv
JPH0194937A (ja) * 1987-10-06 1989-04-13 Yokohama Yushi Kogyo Kk 微粉状ミネラル類の被覆物の製造方法
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
AU2900889A (en) 1987-12-24 1989-07-19 Thomas Julius Borody Orthostatic lavage solutions
AU3367589A (en) 1988-04-05 1989-11-03 Dale Driver Dietary mineral sulfur supplement
JPH0816061B2 (ja) 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
IT1229568B (it) 1989-04-17 1991-09-04 Giuliani Spa Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
NZ249745A (en) 1992-03-11 1996-10-28 Procter & Gamble Psyllium drink mix having granulated base
AU5679794A (en) 1992-11-24 1994-06-22 Block Drug Company Inc., The Pharmaceutical compositions for use in gastrointestinal washes
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5498425A (en) 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
DE69627170T2 (de) 1996-05-08 2004-03-04 Aronchick, Graig A. Nichtwässrige abführmittel für den kolon
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
KR100529512B1 (ko) 1997-04-18 2005-11-22 얀센 파마슈티카 엔.브이. 장 세척 촉진을 위한 5ｈｔ3 길항제의 용도
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
WO2000025744A1 (en) 1998-10-30 2000-05-11 Mcneil-Ppc, Inc. Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof
US6645481B1 (en) 2000-09-28 2003-11-11 Braintree Laboratories, Inc. Method of achieving overnight laxation and control of bowel function
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
AUPR590701A0 (en) 2001-06-25 2001-07-19 Colocaps Pty Ltd Laxative preparation
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
US20040071779A1 (en) 2002-10-09 2004-04-15 Keiser Dale Arthur Gelled laxative compositions
US7291324B2 (en) 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
ATE419857T1 (de) 2003-07-09 2009-01-15 Braintree Lab Verwendung von abführmittel zur behandlung des reizdarmsyndroms
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
GB0409104D0 (en) 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
EP2281562A3 (en) 2004-06-04 2011-11-23 Braintree Laboratories, Inc. Method of bowel cleansing
WO2007013093A2 (en) 2005-04-01 2007-02-01 Shiv Prakash Laxative formulation containing a triphala extract
WO2006118562A1 (en) 2005-04-29 2006-11-09 Inkine Pharmaceutical Company, Inc. Purgative composition and uses thereof
EP1877039A4 (en) 2005-05-06 2010-08-18 Salix Pharmaceuticals Inc Polyethylene glycol GUT CLEANING COMPOSITION
US20070087056A1 (en) 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070082061A1 (en) 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
EP1976520B1 (en) 2005-12-29 2011-04-27 Braintree Laboratories, Inc. Kit comprising an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
AU2008253583A1 (en) 2007-05-17 2008-11-27 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
EP2211838A2 (en) 2007-10-17 2010-08-04 Thomas Jefferson University Bowel purgative and uses thereof
JP2011510020A (ja) 2008-01-16 2011-03-31 ブレーントリー ラボラトリーズ インコーポレーティッド 硫酸塩による予防法および治療法
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US20100255122A1 (en) 2009-04-02 2010-10-07 Garren Mary L Edible gelatin bowel preparation and bowel cleansing method
ES2761297T3 (es) 2009-04-21 2020-05-19 Dale R Bachwich Sistema de lavado de colon
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
GB0912487D0 (en) 2009-07-17 2009-08-26 Norgine Bv Improvements in and relating to colon cleansing compositions
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
CA2792647A1 (en) 2010-03-10 2011-09-15 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
EP2544543A1 (en) 2010-03-12 2013-01-16 Scott Cordray Method of treatment
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
US20130189377A1 (en) 2010-07-27 2013-07-25 Norgine Bv Compositions
BR112013010884A2 (pt) 2010-11-04 2016-08-02 Norgine Bv formulações compreendendo polietileno glicol
DK2651415T3 (da) 2010-12-13 2020-11-30 Rite Prep Pty Ltd Mave- og tyktarmsformuleringer og fremgangsmåder til fremstilling og brug af dem
WO2012091049A1 (ja) * 2010-12-28 2012-07-05 大鵬薬品工業株式会社 口腔内崩壊錠剤
RU2651751C2 (ru) 2011-01-28 2018-04-23 Уильям А. ШЕЙВЕР Способ, композиция и набор для чистки кишечника
JP2014504628A (ja) 2011-01-31 2014-02-24 ノージーン ビーブイ 組成物の改良及び組成物関連
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
RS56574B1 (sr) 2011-04-15 2018-02-28 Braintree Laboratories Inc Sulfatne soli za popravljanje tranzitnog vremena
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
WO2013044085A1 (en) 2011-09-23 2013-03-28 Subramanian Veerappan Sellappan A solid, edible, chewable laxative composition
JP6240610B2 (ja) 2011-10-27 2017-11-29 サリックス ファーマシューティカルズ，インコーポレイテッド 電解質下剤
US9149493B2 (en) 2011-11-28 2015-10-06 Alfa Wassermann Spa Compositions for bowel cleansing and use thereof
AU2013308403B2 (en) 2012-08-29 2019-02-07 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
EP3473248B1 (en) 2012-09-11 2022-01-05 Norgine BV Compositions comprising polyethylene glycol and alkali metal or alkaline earth metal sulphates for use as colon cleansing compositions
US20140087007A1 (en) 2012-09-27 2014-03-27 Braintree Laboratories, Inc. Bowel cleansing preparations
AU2014227598B2 (en) 2013-03-15 2018-12-06 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof

Also Published As

Publication number Publication date
AU2020213378A1 (en) 2020-08-27
EP2968174B1 (en) 2019-10-16
US20180207200A1 (en) 2018-07-26
BR112015019776A2 (pt) 2017-07-18
HRP20192227T1 (hr) 2020-02-21
DK2968174T3 (da) 2019-12-16
PT2968174T (pt) 2020-01-15
CN105142617B (zh) 2018-08-03
US9919007B2 (en) 2018-03-20
CA2903283C (en) 2023-09-05
EA201992382A2 (ru) 2020-02-28
JP6441890B2 (ja) 2018-12-19
MX2015012109A (es) 2016-04-15
ES2764462T3 (es) 2020-06-03
PL2968174T3 (pl) 2020-05-18
CN108904462A (zh) 2018-11-30
JP2016514677A (ja) 2016-05-23
EA201992382A3 (ru) 2020-05-31
AU2014227598A1 (en) 2015-08-27
SI2968174T1 (sl) 2020-02-28
WO2014144407A1 (en) 2014-09-18
PE20151543A1 (es) 2015-11-29
ME03656B (me) 2020-07-20
HK1214519A1 (zh) 2016-07-29
WO2014144407A8 (en) 2014-11-20
AU2019201511A1 (en) 2019-03-28
EP2968174A1 (en) 2016-01-20
CN105142617A (zh) 2015-12-09
LT2968174T (lt) 2020-01-10
CA2903283A1 (en) 2014-09-18
EP3563838A1 (en) 2019-11-06
US20160030473A1 (en) 2016-02-04
CY1122387T1 (el) 2020-11-25
EA034234B1 (ru) 2020-01-20
RS59667B1 (sr) 2020-01-31
JP6724114B2 (ja) 2020-07-15
JP2019023244A (ja) 2019-02-14
AU2014227598B2 (en) 2018-12-06
IL241367A0 (en) 2015-11-30
HUE046754T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201591568A1 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12016502355A1 (en) Pharmaceutical composition
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
PH12016502353A1 (en) Pharmaceutical composition
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201692341A1 (ru) Соли дазатиниба
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
CU20170158A7 (es) Derivados sustituidos de 1-arilnaftiridina-3-carboxamidas y su utilidad en el tratamiento o prevención de enfermedades cardiovasculares y renales
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU